Immuno-Oncology

While patients with stage III or IV melanoma who received a higher dose of ipilimumab did live longer than those on a lower dose, there was also greater toxicity.

Jose Lutzky, MD, discusses the importance of proactive patient monitoring with patients receiving immunotherapy treatments.

A recent study has found that pembrolizumab (Keytruda) may be effective in treating patients with mesothelioma.

An ongoing trial is evaluating the combination therapy of interleukin-10 agonist AM0010 and FOLFOX chemotherapy, for patients with metastatic pancreatic cancer.

Richard Carvajal, MD, discusses the importance of a multidisciplinary approach when monitoring patients for immunotherapy toxicities.

After chemotherapy proved unsuccessful, one patient entered a clinical trial of a new combination for immunotherapy for her ovarian cancer.

For patients with non-small cell lung cancer (NSCLC) receiving pembrolizumab, long-term survival rates could reach 25%.

A recent study presented at the 2017 Genitourinary Cancers Symposium found that use of antibiotics could damper the efficacy of checkpoint inhibitors, potentially due to the relationship between gut microbiota and antibiotics.

Richard Carvajal, MD, discusses how to make decisions regarding the dosing limits of immunotherapy agents.

The American Society of Clinical Oncology named Immunotherapy 2.0 as the Advance of the Year, as it continues to move the cancer field forward.

Claire Friedman discusses the factors clinicians should consider when determining an immunotherapy treatment plan for older patients.

Karen Lee explains why it is important for patients to understand immunotherapy and how nurses can help them in patients education.

Immunotherapy agents are drastically changing the treatment landscape – and outcomes – of patients with head and neck cancers.

Nurse practitioner Brianna Hoffner, MSN, NP, RN, discusses the important things to consider for an oncology nurse working with patients being treated with cancer immunotherapies.

Lisa Butterfield discusses what nurses should know when treating patients receiving immunotherapies.

Alex Herrera discusses the response of patients with Hodgkin lymphoma on combination nivolumab/brentuximab vedotin.

Igor Puzanov discusses the rare cardiologic adverse events that can occur when a patient is on checkpoint inhibitors.

Elizabeth Repasky discusses chronic stress and its link to anti-tumor immune reponses.

Christian Capitini discusses the responses to immunotherapy.

Brianna Hoffner reminds oncology nurses to collaborate with colleagues in other departments when treating patients with immune-related adverse events.

Karen Lee discusses the managment of immune-related adverse events in patients who are receiving immunotherapy treatments.

Aside from the approved nivolumab, other immunotherapy combinations are being considered for Hodgkin lymphoma.

Laura Wood explains the education opportunities available to nurses in the field of immunotherapy.

Karen Lee, NP, explains the importance of keeping patients with cancer hopeful but realistic when starting immunotherapies.

Omid Hamid, MD, compares the responses of patients with melanoma on single-agent immunotherapy treatment to those on combination therapy treatments.

Brianna Hoffner, MSN, NP, RN, discusses complex immune-related adverse events and how nurses can go about treating patients.

For multiple myeloa and immunotherapy, combination treatment may be the best pathway to durable responses.